INVENTIVA: Inventiva to participate at several investor conferences in March 2021
Daix (France), February 24, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Frédéric Cren, Chairman, CEO and cofounder of Inventiva, will participate at three upcoming investor conferences in March 2021.
The event details are as follows:
Conference n°1: Credit Suisse Virtual 2021 London Global Healthcare Conference
Event type: One-on-one investor meetings
Date: Tuesday-Thursday, March 2-4, 2021
Format: Virtual event
Event type: Corporate presentation, fireside chat, one-on-one investor meetings
Investegate |INVENTIVA Announcements | INVENTIVA: Inventiva to participate at several investor conferences in March 2021 investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Important Notice
This press release contains forward-looking statements, forecasts and estimates with respect to Inventiva’s clinical trials, clinical trial data releases, clinical development plans and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Ac
Cash position2 at €113.0m as of December 31, 2020 compared to €124.6 million at September 30, 2020 and €35.8 million at December 31, 2019Revenues of €0.4m in 2020 compared to €7.0m in 2019Successful €94.9m3